Literature DB >> 2346907

Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy.

K C Conlon1, W J Urba, J W Smith, R G Steis, D L Longo, J W Clark.   

Abstract

The occurrence of autoimmune disease in patients receiving alpha-interferon (alpha-IFN) therapy has been reported in several studies; these include autoimmune thyroiditis, thrombocytopenia, anemia, exacerbation of psoriasis, and the occurrence of sarcoidosis. The primary mechanism presumably is the emergence of autoantibodies to various structural proteins or receptors. Two studies have recently shown that a significant percentage of patients treated with recombinant alpha-interferon (r alpha-IFN) do form autoantibodies. The authors report six additional cases of development or exacerbation of autoimmune phenomena in patients receiving alpha-IFN therapy. Five of these patients developed symmetric polyarthropathies and the sixth had thyroiditis. The presence of a history of underlying autoimmune disease or baseline serologic abnormalities in five of these patients, including the patient who developed thyroiditis, suggests that alpha-IFN treatment can lead to the exacerbation of an underlying subclinical autoimmune process.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2346907     DOI: 10.1002/1097-0142(19900515)65:10<2237::aid-cncr2820651013>3.0.co;2-5

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  40 in total

1.  Acute autoimmune hemolytic anemia during interferon-alpha therapy for chronic hepatitis C.

Authors:  A Landau; L Castera; C Buffet; G Tertian; G Tchernia
Journal:  Dig Dis Sci       Date:  1999-07       Impact factor: 3.199

2.  Autoimmune thrombocytopenia induced by PEG-IFN-alpha2b plus ribavirin in hepatitis C.

Authors:  Abdurrahman Sagir; Matthias Wettstein; Tobias Heintges; Dieter Häussinger
Journal:  Dig Dis Sci       Date:  2002-03       Impact factor: 3.199

3.  Etanercept treatment to enable successful hepatitis C virus clearance in a patient with rheumatoid arthritis.

Authors:  Alison B Jazwinski; Janet Jezsik; Stacy P Ardoin; Rex M McCallum; Hans L Tillmann
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-11

Review 4.  Current methods for detecting antibodies against erythropoietin and other recombinant proteins.

Authors:  Robin Thorpe; Steven J Swanson
Journal:  Clin Diagn Lab Immunol       Date:  2005-01

5.  Interferon alpha-induced lupus: proof of principle.

Authors:  Timothy B Niewold
Journal:  J Clin Rheumatol       Date:  2008-06       Impact factor: 3.517

6.  De Quervain's Thyroiditis Associated with Interferon-alpha-2b Therapy for Non-Hodgkin's Lymphoma.

Authors:  A Fortis; C Christopoulos; E Chrysadakou; E Anevlavis
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

7.  Development of transient autoimmune hepatitis during interferon treatment of chronic hepatitis B.

Authors:  J Cianciara; T Laskus
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

Review 8.  Interferon-alpha in childhood haematological malignancies.

Authors:  R Simkó; K Nagy
Journal:  Postgrad Med J       Date:  1996-12       Impact factor: 2.401

Review 9.  Drug-induced taste and smell disorders. Incidence, mechanisms and management related primarily to treatment of sensory receptor dysfunction.

Authors:  R I Henkin
Journal:  Drug Saf       Date:  1994-11       Impact factor: 5.606

10.  Irreversible pulmonary hypertension associated with the use of interferon alpha for chronic hepatitis C.

Authors:  Sonu Dhillon; Anshul Kaker; Aneil Dosanjh; Deepa Japra; David H Vanthiel
Journal:  Dig Dis Sci       Date:  2010-04-22       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.